Treating organ inflammation

LSALT peptide (Metablok) is designed to target acute organ inflammation in the lungs, liver and kidneys.

Investor Relations

Get stock information, press releases, financials and management’s discussion and analysis.

Arch Biopartners Science

Learn about the company’s medical trials, clinical research and journal publications.

The Company

Find out why Arch is distinct – our approach, and the team behind our science.

Developing drugs to prevent inflammation and organ injury

Arch Biopartners is a late-stage clinical trial company focused on preventing inflammation and organ injury.

Organ inflammation is a frequent result of common injuries and diseases and presents an unmet need with no effective treatments in the market today.

Arch has built a novel, therapeutic drug platform of new candidates led by LSALT peptide, developed to inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP1) pathway.

Arch Biopartners Approach

The company has a long history of working closely with the scientific community, universities and research institutions. Arch Biopartners mission is to advance and build the value of select therapeutic innovations, develop the most promising intellectual property, and create value for its investors.

Find out more about the Company, our focus and the fundamentals that make Arch unique.

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at the University of Calgary Cumming School of Medicine is now completing final preparations and training to enable the start of patient recruitment in September. University Health Network and Unity Health Toronto are ...

Full Release

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissueArch continues to perform a Phase II trial for LSALT peptide targeting cardiac surgery-associated-AKI Drug toxins and CS-AKI account for up to 50% of all AKI occurring in hospitals, for which there is no treatment available TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arch ...

Full Release

Find out about the company’s recent advancements, new patents, corporate filings, information for investors and all progress updates on active clinical trials.

Browse all of the company’s material news releases.
Read the latest releases when they are published here or via email by subscribing to email alerts and news.

Arch Biopartners key stock indicators.

The Stock Performance page displays current and historical data for both of the Arch Biopartners symbols on the TSX Venture Exchange in Canada and the OTCQB Venture Exchange in the USA.

Please be sure to subscribe for email updates when the company issues news releases and to receive announcements of new scientific data and company events and presentations.

The company’s reports and filings include current filings and an archive for investors and the public to use for research and review:

View the complete Arch Biopartners Inc. filings archives at the SEDAR website here .

Investor Information

Stock data, insights, filings, latest news.

Subscribe for email updates

Get email alerts when news is published

Latest Scientific Publications

Arch Biopartners science team’s published findings and articles in peer-reviewed journals.

Developing select technologies

Arch Biopartners key technologies, scientists, publications and ongoing trials.

LSALT peptide (Metablok), is the company’s lead drug candidate targeting organ inflammation in the lungs, liver and kidneys.

LSALT peptide trials and development

In 2024, the company is sponsoring a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI).

The CS-AKI trial began dosing patients in March 2024. The trial began with three active hospital sites in Turkey with a hospital site in Canada also joining in March 2024. The complete study is planned to include up to 240 patients in Turkey, Canada and the United States.

March 2024, dosing of first patient in Turkey marking the commencement of the Phase II CS-AKI trial.
March 2024, publication of previous Phase II trial results providing further scientific rationale to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications.
June 2023, FDA permission to proceed with a new Phase II trial targeting CS-AKI.
April 2023, successful completion of a Phase I dose escalation trial.

Find out more about our science platforms and about LSALT peptide clinical trials and development targeting the treatment and prevention of common injuries and diseases related to organ inflammation.

An experienced group of scientists working together to develop the Arch science platforms.

Science and Research Teams

Current work on LSALT peptide is directed by Arch’s larger Treatments for Inflammation Team, led by Dr. Daniel Muruve Ph. D. (Arch Biopartners CSO), Dr. Justin Macdonald Ph. D., and Dr. Arthur Lau Ph. D (Arch Biopartners Project Director), who are primarily based at the University of Calgary. Dr. David Luke, BScPhm, PharmD, is a Strategic Advisor working to support the Board of Directors and the company’s ongoing clinical trials with LSALT peptide.
The DPEP1 Inflammation Pathway and LSALT Peptide (Metablok) were discovered by the Metablok team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D., Jennifer Rahn B Sc., M Sc. and their colleague Dr. Paul Kubes at the University of Calgary.

The Arch science team also includes:

Dr. Randall Irvin Ph. D., Professor Emeritus at the University of Alberta, whose work on the BORG Peptide is not currently under commercial development.

The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.

Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors